ADC Therapeutics (ADCT) Notes Payables (2022 - 2023)
ADC Therapeutics (ADCT) posted Notes Payables of $14.3 million for Q3 2023, up 3.09% sequentially from $13.9 million in Q2 2023, and up 14.63% YoY from $12.5 million in Q3 2022.
ADC Therapeutics (ADCT) Notes Payables (2022 - 2023) Analysis & Trends
ADC Therapeutics has reported Notes Payables for 2 years, with the latest figure at $14.3 million in Q3 2023.
- Quarterly Notes Payables rose 14.63% year-over-year to $14.3 million in Q3 2023, while the trailing twelve-month figure through Sep 2023 was $14.3 million (up 14.63% YoY) and the FY2022 annual result came in at $12.5 million, changed N/A from the prior year.
- Notes Payables climbed to $14.3 million in Q3 2023 per ADCT's latest filing, from $13.9 million in the prior quarter.
- Over five years, Notes Payables peaked at $14.3 million in Q3 2023 and troughed at $12.5 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | ADC Therapeutics | 148.95 Mn | -70.15 Mn | 17.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 14.33 Mn |
| Jun 30, 2023 | 13.90 Mn |
| Mar 31, 2023 | 13.53 Mn |
| Dec 31, 2022 | 12.47 Mn |
| Sep 30, 2022 | 12.50 Mn |